Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Teicoplanin

K W Shea1, B A Cunha

  • 1Infectious Disease Division, Winthrop-University Hospital, Mineola, New York, USA.

The Medical Clinics of North America
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Teicoplanin is a safe and effective glycopeptide antibiotic for treating gram-positive infections, showing efficacy comparable or superior to vancomycin with fewer side effects. Its favorable pharmacokinetics allow for convenient dosing regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Viral influenza-like illnesses: dynamic interrelationships during the 2015-2016 influenza season in hospitalized patients.

The Journal of hospital infection·2017
Same author

Editor's Mail.

Postgraduate medicine·2016
Same author

Are atypical lymphocytes present with viral influenza-like illnesses (ILIs) in hospitalized adults?

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2016
Same author

Problems+Solutions.

Postgraduate medicine·2016
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Gram-positive bacterial infections pose a significant threat, particularly in immunocompromised individuals.
  • Vancomycin is a standard treatment, but concerns regarding toxicity and resistance exist.
  • Teicoplanin, a novel glycopeptide antibiotic, emerged as a potential alternative.

Purpose of the Study:

  • To evaluate the efficacy and safety of teicoplanin in treating gram-positive infections.
  • To compare teicoplanin's in vitro activity with vancomycin.
  • To assess teicoplanin's tolerability and pharmacokinetic profile.

Main Methods:

  • In vitro susceptibility testing against gram-positive organisms.
  • Clinical trials, including open-label and comparative studies.

Related Experiment Videos

  • Pharmacokinetic analysis of teicoplanin dosing and administration.

    • Main Results:

    • Teicoplanin demonstrated in vitro activity equal to or greater than vancomycin against most gram-positive bacteria.
    • Clinical trials showed teicoplanin to be well-tolerated, with rare treatment discontinuation.
    • Nephrotoxicity was uncommon, even with concurrent use of nephrotoxic agents like aminoglycosides or cyclosporin A.

    Conclusions:

    • Teicoplanin is an effective and safe alternative to vancomycin for gram-positive infections.
    • Favorable pharmacokinetics support convenient administration routes (intramuscular and intravenous) and once-daily maintenance dosing.
    • Teicoplanin offers a valuable therapeutic option for both normal and immunocompromised hosts.